tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

KYMR Stock Latest News

Kymera Therapeutics Announces New Chief Legal Officer
Company AnnouncementsKymera Therapeutics Announces New Chief Legal Officer
6d ago
8K
KYMR
Kymera Therapeutics appoints Adams as Chief Legal Officer, Corporate Secretary
PremiumThe Fly
Kymera Therapeutics appoints Adams as Chief Legal Officer, Corporate Secretary
6d ago
KYMR
Kymera Therapeutics: Promising Clinical Developments and Strategic Positioning in STAT6 Landscape Justify Buy Rating
PremiumRatings
Kymera Therapeutics: Promising Clinical Developments and Strategic Positioning in STAT6 Landscape Justify Buy Rating
25d ago
KYMR
Kymera Therapeutics’ Earnings Call: Optimism and Strategic Progress
PremiumCompany Announcements
Kymera Therapeutics’ Earnings Call: Optimism and Strategic Progress
27d ago
KYMR
Kymera Therapeutics: Promising Developments in STAT6 Degrader KT-621 Drive Buy Rating
PremiumRatings
Kymera Therapeutics: Promising Developments in STAT6 Degrader KT-621 Drive Buy Rating
28d ago
KYMR
Positive Outlook for Kymera Therapeutics Amid Promising KT-621 Developments and Strong Financial Position
PremiumRatingsPositive Outlook for Kymera Therapeutics Amid Promising KT-621 Developments and Strong Financial Position
28d ago
KYMR
Kymera Therapeutics: Strategic Advancements and Financial Strength Drive Buy Rating
Premium
Ratings
Kymera Therapeutics: Strategic Advancements and Financial Strength Drive Buy Rating
28d ago
KYMR
Kymera Therapeutics: Promising Developments and Strong Financial Position Support Buy Rating
Premium
Ratings
Kymera Therapeutics: Promising Developments and Strong Financial Position Support Buy Rating
28d ago
KYMR
Kymera Therapeutics: Promising KT-621 Progress and Strong Financial Position Justify Buy Rating
PremiumRatings
Kymera Therapeutics: Promising KT-621 Progress and Strong Financial Position Justify Buy Rating
28d ago
KYMR
Kymera Therapeutics Reports Q2 2025 Progress and Partnerships
PremiumCompany Announcements
Kymera Therapeutics Reports Q2 2025 Progress and Partnerships
28d ago
KYMR
Kymera Therapeutics: Strong Financials and Promising Clinical Results Justify Buy Rating
PremiumRatings
Kymera Therapeutics: Strong Financials and Promising Clinical Results Justify Buy Rating
29d ago
KYMR
Kymera Therapeutics reports Q2 EPS (95c), consensus (80c)
PremiumThe Fly
Kymera Therapeutics reports Q2 EPS (95c), consensus (80c)
29d ago
KYMR
Kymera Therapeutics sees cash runway into 2H28
PremiumThe FlyKymera Therapeutics sees cash runway into 2H28
29d ago
KYMR
Kymera Therapeutics transferred with Buy rating at B. Riley
Premium
The Fly
Kymera Therapeutics transferred with Buy rating at B. Riley
1M ago
KYMR
Is KYMR a Buy, Before Earnings?
Premium
Pre-Earnings
Is KYMR a Buy, Before Earnings?
1M ago
KYMR
Kymera Therapeutics initialed with Early-Stage Biotech at Goldman Sachs
PremiumThe Fly
Kymera Therapeutics initialed with Early-Stage Biotech at Goldman Sachs
2M ago
KYMR
Gilead estimates Q2 acquired IPR&D expenses of $61M
PremiumThe Fly
Gilead estimates Q2 acquired IPR&D expenses of $61M
2M ago
GILD
KYMR
Morgan Stanley Puts These 2 Stocks on Its Buy List — Here’s Why You Should Follow
PremiumStock Analysis & Ideas
Morgan Stanley Puts These 2 Stocks on Its Buy List — Here’s Why You Should Follow
2M ago
KYMR
PRMB
Kymera Therapeutics: Buy Rating Backed by Innovative Drug Discovery and Strategic Partnerships
PremiumRatings
Kymera Therapeutics: Buy Rating Backed by Innovative Drug Discovery and Strategic Partnerships
2M ago
KYMR
Kymera Therapeutics assumed with an Overweight at Morgan Stanley
PremiumThe FlyKymera Therapeutics assumed with an Overweight at Morgan Stanley
2M ago
SNY
GILD
Kymera Therapeutics management to meet with B. Riley
Premium
The Fly
Kymera Therapeutics management to meet with B. Riley
2M ago
KYMR
Kymera Therapeutics price target raised to $54 from $51 at BofA
Premium
The Fly
Kymera Therapeutics price target raised to $54 from $51 at BofA
2M ago
SNY
KYMR

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >